Previous 10 | Next 10 |
Today, we take our first in-depth look at Daré Bioscience, which came public six years back and is now deep in 'Busted IPO' territory. However, the company looks set to garner FDA approval for its primary drug candidate. A full investment analysis on Daré Bioscience is p...
Gainers: Obalon Therapeutics (OBLN) +438%.Caladrius Biosciences (CLBS) +121%.Adamis Pharmaceuticals (ADMP) +72%.Steel Connect (STCN) +54%.Titan Medical (TMDI) +52%.Tiziana Life Sciences (TLSA) +50%.Iterum Therapeutics (ITRM) +40%.Dare Bioscience (DARE) +33%.17 Education & T...
Caladrius Biosciences (CLBS) +120%.Aptorum Group (APM) +61% as Canada approves early-stage infection drug trial.Steel Connect (STCN) +54%.Dare Bioscience (DARE) +39%.ENDRA Life Sciences (NDRA) +36%.Lineage Cell Therapeutics (LCTX) +34%.Inuvo (INUV) +33%.eMagin Corporation (EMAN) +28...
Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Tenax Therapeutics (TENX)...
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIO...
Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...
Daré Bioscience ([[DARE]] -10.0%) reports topline data from Phase 3 DARE-BVFREE trial evaluating DARE-BV1 for the treatment of bacterial vaginosis. The trial met its primary endpoint demonstrating that a single administration of DARE-BV1 was superior to placebo, though reported...
Eastman Kodak (KODK) +76%. as DFC says no laws were broken.Greenland Technologies Holding (GTEC) +60% on launching 'electric industrial vehicle market' divisionObalon Therapeutics (OBLN) +52%.Oncternal Therapeutics (ONCT) +27% on presentation of interim phase 1/2 data...
DARE-BV1 met the primary endpoint of the study and all pre-specified secondary efficacy endpoints; demonstrated significantly greater clinical cure rates compared to placebo DARE-BV1 has Fast Track and QIDP designatio...
Daré Bioscience, Inc. (DARE) Q3 2020 Results Earnings Conference Call November 12, 2020, 04:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Jason Kolb...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...